Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGM | P11217 | 3/20 | 0.57 |
| ▸ | TK2 | O00142 | 2/20 | 0.56 |
| ▸ | P2RY2 | P41231 | 6/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | CDA | P32320 | 1/20 | 0.53 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.52 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.52 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.52 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16871785 | 1.00 | PYGM (0.57) | PYGMTK2P2RY2MAPTCDA | |
| SCHEMBL18486326 | 0.86 | DNPH1 (0.53) | P2RY2 | |
| SCHEMBL17363678 | 0.85 | DNPH1 (0.62) | P2RY2 | |
| SCHEMBL17363679 | 0.85 | DNPH1 (0.62) | P2RY2 | |
| SCHEMBL2577658 | 0.84 | P2RY2 (0.74) | PYGMTK2P2RY2SLC28A1SLC28A2 | |
| SCHEMBL28937870 | 0.84 | P2RY2 (0.74) | PYGMTK2P2RY2SLC28A1SLC28A2 | |
| SCHEMBL16871732 | 0.82 | TK2 (0.46) | PYGMTK2P2RY2 | |
| SCHEMBL16871735 | 0.82 | TK2 (0.46) | PYGMTK2P2RY2 | |
| SCHEMBL5872491 | 0.81 | TK1 (0.60) | TK2 | |
| SCHEMBL5872494 | 0.81 | TK1 (0.60) | TK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3130597-B1 | OLIGONUCLEOTIDE HAVING A NON-NATURAL NUCLEOTIDE AT THE 5'-TERMINAL | KYOWA KIRIN CO LTD (JP) | 2021-11-10 | — | — | EP | disclosed |
| EP-2891717-B1 | OLIGONUCLEOTIDE | KYOWA KIRIN CO LTD (JP) | 2020-04-29 | — | — | EP | disclosed |
| US-10378011-B2 | Oligonucleotide | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2019-08-13 | — | — | US | disclosed |
| US-10342819-B2 | Oligonucleotide having non-natural nucleotide at 5′-terminal thereof | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2019-07-09 | — | — | US | disclosed |
| US-20170354673-A1 | OLIGONUCLEOTIDE HAVING NON-NATURAL NUCLEOTIDE AT 5'-TERMINAL THEREOF | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2017-12-14 | — | — | US | disclosed |
| EP-3130597-A1 | OLIGONUCLEOTIDE HAVING NON-NATURAL NUCLEOTIDE AT 5'-TERMINAL THEREOF | Kyowa Hakko Kirin Co., Ltd. (JP) | 2017-02-15 | — | — | EP | disclosed |
| US-20150376611-A1 | OLIGONUCLEOTIDE | KYOWA KIRIN CO., LTD. (JP) | 2015-12-31 | — | — | US | disclosed |
| EP-2891717-A1 | OLIGONUCLEOTIDE | Kyowa Hakko Kirin Co., Ltd. (JP) | 2015-07-08 | — | — | EP | disclosed |
| US-6235887-B1 | MEASUREMENT, CALIBRATION OF OLIGONUCLEOTIDE BINDING TO NUCLEIC ACIDS | ISIS PHARMACEUTICALS, INC. | 2001-05-22 | — | — | US | disclosed |
| US-5484908-A | URACIL OR CYTOSINE DERIVATIVES, DETECTION OF DNA SEQUENCES | GILEAD SCIENCES, INC. (US) | 1996-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10378011-B2 | Oligonucleotide | HNRNPA3, AGO2, RBM3 | PYGM 3180/4885TK2 2753/4885P2RY2 4450/4885 |
| US-10342819-B2 | Oligonucleotide having non-natural nucleotide at 5′-terminal thereof | RNGTT, UPF1, NSUN3 | PYGM 3344/4885TK2 580/4885P2RY2 2497/4885 |
| US-20170354673-A1 | OLIGONUCLEOTIDE HAVING NON-NATURAL NUCLEOTIDE AT 5'-TERMINAL THEREOF | RNGTT, UPF1, NSUN3 | PYGM 3314/4885TK2 592/4885P2RY2 2562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.